{"entity":{"id":"nct05563844","kind":"trial","name":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","aka":[],"tldr":"A phase 2 trial of PM 8.4 mg/m^2 in diffuse large B-cell lymphoma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.","summary":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) is a phase 2 interventional study registered as NCT05563844 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 74 participants enrolled, started 2022-11-08 and due to reach its primary completion in 2026-12-30. Interventions recorded: PM 8.4 mg/m^2 and PM 11.2 mg/m^2.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05563844","url":"https://clinicaltrials.gov/study/NCT05563844"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["chengdu-zenitar-biomedical-technology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05563844","phase":"2","setting":"An Open-label, Multi-center Phase II Clinical Study on the Efficacy and Safety of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","participation":[{"nct":"NCT05563844","source":"https://clinicaltrials.gov/study/NCT05563844","fetchedAt":"2026-10-07T16:53:46.156Z","studySha256":"ecea897bcb6e07f3dfa15b2e5439791dae60794ff2a8d79c7e5d828c6e20bd69","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-02-04","leadSponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":74,"enrolmentType":"ACTUAL","siteCount":2,"recruitingSiteCount":0,"countries":["China"]}],"started":"2022-11-08","startedType":"actual","enrolled":74,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05563844/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"company":[{"id":"chengdu-zenitar-biomedical-technology","kind":"company","name":"Chengdu Zenitar Biomedical Technology","route":"/companies/chengdu-zenitar-biomedical-technology/"}]}}